| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Total revenue-License | 0 | - | - | - |
| Total revenue | 0 | 1,300 | - | 100 |
| Research and development | 28,535 | 22,267 | 38,893 | 67,632 |
| General and administrative | 5,277 | 6,422 | 7,904 | 93,366 |
| Total operating expenses | 33,812 | 28,689 | 46,797 | 160,998 |
| Loss from operations | -33,812 | -27,389 | -46,797 | -160,898 |
| Gain related to transaction with acquirer | 0 | 0 | - | 2,021,498 |
| Interest expense | 3,181 | 3,141 | - | 5,361 |
| Interest income | 1,783 | 2,124 | 2,892 | 2,741 |
| Other income (expense), net | -46 | -246 | 41 | 33 |
| Total other income (expense) | -1,444 | -1,263 | 2,933 | 2,018,911 |
| Income (loss) before income tax expense | -35,256 | -28,652 | -43,864 | 1,858,013 |
| Provision for income taxes | 0 | 2 | - | 2 |
| Net income (loss) | -35,256 | -28,654 | -43,864 | 1,858,011 |
| Basic (in dollars per share) | -2.28 | -1.85 | -2.84 | 127.1 |
| Basic (in shares) | 15,478,000 | 15,468,000 | 15,468,000 | 14,619,000 |
| Diluted (in dollars per share) | -2.28 | -1.85 | -2.84 | 125.48 |
| Diluted (in shares) | 15,478,000 | 15,468,000 | 15,468,000 | 14,807,000 |
Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (INBX)